Institute For Clinical And Experimental Medicine

At the Institute For Clinical And Experimental Medicine in Prague, a major focus is cardiovascular disease and related metabolic disorders, with studies in heart failure, myocardial infarction, atherosclerosis, hypertension, obesity, and lipid disorders. These trials are exploring new ways to reduce risk, improve symptoms, and better control long-term disease progression.

• Testing new approaches for acute and chronic heart failure and cardiogenic shock
• Evaluating treatments for atherosclerotic cardiovascular disease, calcific aortic valve stenosis, and cardiac remodeling
• Studying therapies aimed at improving cholesterol, triglycerides, and inflammation-related cardiovascular risk

This research also includes efforts to improve outcomes after heart events and to support patients with complex cardiometabolic conditions that often require long-term care.

The Department of Hepatogastroenterology is strongly active in trials for digestive system diseases and liver disorders, including Crohn’s disease, ulcerative colitis, primary biliary cholangitis, cirrhosis, and alpha-1 antitrypsin deficiency-associated liver disease. The goal is to test new therapies and better understand how to control inflammation, scarring, and disease progression.

• Assessing treatments for inflammatory bowel disease such as Crohn’s disease and ulcerative colitis
• Investigating therapies for chronic liver disease, including cholestatic and fibrotic conditions
• Exploring ways to improve long-term disease control and reduce complications in gastrointestinal and liver disorders

Several studies at the site focus on improving symptoms, maintaining remission, and slowing disease-related damage in hepatogastroenterology.

A substantial part of the trial portfolio addresses kidney disease and transplant medicine, including chronic kidney disease, IgA nephropathy, acute kidney injury, and kidney transplant rejection. These studies are designed to improve graft outcomes, protect kidney function, and refine care for patients with advanced renal disease.

• Evaluating therapies for kidney transplant rejection, including antibody-mediated and microvascular inflammation-related complications
• Studying treatments for IgA nephropathy and progressive chronic kidney disease
• Testing strategies to prevent or reduce acute kidney injury and improve outcomes after transplantation or surgery

The site also investigates approaches for patients awaiting transplant and for those with complex renal disease combined with other chronic conditions.

Clinical trials here also cover type 1 diabetes, type 2 diabetes, obesity, and broader metabolic disease. Research is aimed at preserving insulin production, improving glucose control, and reducing complications such as diabetic retinopathy and diabetic foot disease.

• Testing therapies for early type 1 diabetes to help preserve beta-cell function
• Studying treatments for diabetic eye disease and long-term metabolic safety
• Exploring options for weight management and metabolic risk reduction in people with obesity or overweight

These studies reflect a strong interest in preventing complications and improving day-to-day disease management in metabolic disorders.

The research program also includes trials in pulmonary arterial hypertension, immune system diseases, and selected rare disorders. Conditions studied include PAH, amyloidosis with cardiomyopathy, erythropoietic protoporphyria, and complement-related diseases. The aim is to assess new therapies that may improve function, symptoms, and disease control.

• Evaluating treatments for pulmonary arterial hypertension and related long-term outcomes
• Studying therapies for transthyretin amyloid cardiomyopathy and other rare protein-related conditions
• Investigating immune-targeted approaches for uncommon inflammatory and hematologic disorders

This area highlights the site’s role in advancing care for patients with complex and less common diseases that often have limited treatment options.

The site also conducts research in surgical procedures, vascular disease, and critical care, including chronic limb-threatening ischemia, diabetic foot ulcers, and fluid overload in hospitalized patients. These trials focus on improving recovery, tissue perfusion, and overall clinical outcomes.

• Testing new strategies for limb ischemia and wound-related complications in diabetes
• Evaluating approaches to support patients with fluid overload or high-risk perioperative states
• Assessing treatments intended to improve healing, circulation, and postoperative safety

At the Institute For Clinical And Experimental Medicine, this line of research connects vascular care with broader surgical and hospital-based treatment needs.